Stay updated on T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial
Sign up to get notified when there's something new on the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page.

Latest updates to the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA new revision entry 'Revision: v3.3.3' appears in the Study Record Versions. The footer no longer displays 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision: v3.3.2 is now shown, replacing Revision: v3.2.0; this is a minor website update and does not affect trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedA government funding/operating-status notice banner was removed from the page. This banner did not affect the clinical trial record content or historical record details.SummaryDifference0.8%

- Check59 days agoChange DetectedThe record history shows a change to Study Status (2021-01-19) and a subsequent change to Recruitment Status (2022-11-07) for the TRAEMOS study.SummaryDifference0.1%

- Check88 days agoChange DetectedAdded a government-funding/status notice and upgraded version to v3.2.0; removed the old v3.1.0 tag.SummaryDifference13%

- Check95 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.3%

Stay in the know with updates to T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page.